High-Intensity Focused Ultrasound (HIFU): Comprehensive Overview
What is HIFU?
HIFU uses timed bursts of high-frequency ultrasound (typically 4 MHz, ranging up to 10 MHz) to create coagulation necrosis in targeted tissue by heating it to 70°C or higher, achieving tissue destruction without incisions or radiation. 1 The same piezoceramic element used for focal therapy can also provide ultrasound imaging, allowing integration of therapeutic and diagnostic components in a single probe 1.
Mechanism of Action
HIFU achieves tissue destruction through three primary mechanisms 2:
- Thermal effects: Direct heating causing coagulative necrosis
- Mechanical effects: Tissue disruption from acoustic pressure
- Cavitation: Formation and collapse of microbubbles causing cellular damage
The focused ultrasound beams converge at a specific focal point, delivering high-energy pulses in a spatially coordinated manner while minimizing damage to surrounding tissue 2.
Clinical Indications
Gynecological Applications
Uterine Fibroids (MR-Guided Focused Ultrasound)
MRgFUS is an FDA-approved, non-invasive treatment option for symptomatic uterine fibroids, particularly for patients desiring uterus preservation or who are poor surgical candidates. 3
Key efficacy data 3:
- 18% fibroid diameter reduction at 2 years (vs. no change with placebo)
- Reintervention rate: 4% at 1 year, 13% at 2 years, 19% at 3 years, 23% at 4 years
- Major adverse event rate: 0.2% (compared to 12.6% for surgical approaches)
- Significantly greater improvement in quality of life compared to placebo
- Higher reintervention rate than uterine artery embolization (UAE): 30% vs. 13% at 2 years
- Less symptom control than UAE but associated with decreased postprocedural pain, reduced narcotic use, and faster recovery
- Procedure duration: 6.75 hours (vs. 2.3 hours for UAE), occasionally performed over 2 days
- Similar quality of life outcomes to laparoscopic myomectomy at 5 years
Patient selection criteria 3:
- Fewer than 6 leiomyomas or total fibroid volume <900 cm³
- Patients interested in uterus-preserving therapy
- Poor surgical candidates
- Fibroids not surgically resectable
Fertility considerations 3, 4:
- No randomized controlled trials assessing fertility outcomes
- Pregnancy is possible after MRgFUS
- Myomectomy remains the first-line choice for women planning future pregnancy 4
- Limited evidence suggests myomectomy may be superior to MRgFUS for fertility preservation
Prostate Cancer
Current Status
HIFU for prostate cancer remains investigational for whole-gland treatment of high-risk localized disease due to poor long-term oncological outcomes and should not be considered a reasonable alternative to established curative treatments. 5
Whole-gland treatment outcomes 5, 6, 7:
- Negative biopsy rates: 35-95%
- 5-year disease-free survival: 61.2-95%
- 7-8 year disease-free survival: 69-84%
- PSA nadirs: 0.04-1.8 ng/mL
- Mean follow-up: 6.4-76.8 months
Focal therapy for localized disease 5, 8:
- Interest has shifted to treating small low- or intermediate-risk unifocal tumors with focal HIFU 5
- 88% failure-free survival at 5 years (with one repeated focal HIFU session allowed in 25% of patients) 5
- Low treatment-related toxicity: 4% decrease in pad-free continence, 0.4-point reduction in erectile function scores 5
- Should only be performed within clinical trials or well-designed prospective registries 5
- Tumor location influences oncologic outcome; limiting apical treatment to minimize morbidity increases cancer persistence risk 8
Technical limitations 5:
- Challenges delivering energy to anterior prostate in large glands
- US energy typically delivered from rectal cavity
Benign Prostatic Hyperplasia (BPH)
HIFU for BPH is investigational and should not be offered outside of clinical trials. 1 The therapy has been described as "moderately promising" but requires additional long-term studies 1.
Essential Tremor
MRgFUS thalamotomy is an FDA-approved treatment for medication-refractory essential tremor with confirmed safety and efficacy in randomized controlled trials. 9
Indications 9:
- Confirmed diagnosis of essential tremor
- Failure to respond to, intolerance of, or medical contraindication to at least 2 medications (one must be first-line)
- Appendicular tremor interfering with quality of life
Contraindications 9:
- Bilateral MRgFUS thalamotomy
- Contralateral to previous thalamotomy
- Cannot undergo MRI
- Skull density ratio (cortical to cancellous bone) <0.40
Mechanism 9:
- Combines high-intensity focused ultrasound with real-time MRI thermographic imaging
- Incisionless thermal ablation targeting ventral intermediate nucleus (VIM) of thalamus
- Avoids skin incision, bone craniostomy, and physical brain tissue traversal
Other Applications
Placenta accreta spectrum 10:
- High-intensity focused ultrasonography used with hysteroscopic resection for persistent placental tissue
- Not recommended routinely due to limited data, frequent adverse events (uterine perforations, hemorrhagic shock), and need for repeat procedures in one-third of patients
Procedural Technique
MR-Guided Focused Ultrasound (Fibroids)
Procedure characteristics 3:
- Non-invasive, outpatient procedure
- Real-time MRI guidance with thermographic imaging
- Multiple sonications targeting fibroid tissue
- Duration: typically 6.75 hours, occasionally over 2 days
- Immediate tissue destruction effect comparable to surgery
Prostate HIFU
- Transrectal probe delivery
- Real-time ultrasound imaging integrated with therapeutic element
- Neoadjuvant transurethral resection of prostate (TURP) combined with HIFU since 2000 to reduce prostate size and minimize side effects 6, 7
- Approximately 65,000 prostate cancer patients treated worldwide, predominantly with Ablatherm device 6
Essential Tremor Thalamotomy
Procedure details 9:
- MRI-guided targeting of VIM thalamus
- Real-time temperature monitoring
- Continuous control through thermographic imaging
- No physical brain penetration required
Side Effects and Complications
Gynecological HIFU (Uterine Fibroids)
Common adverse events 11:
- Lower abdominal/pelvic pain: 36.1% (95% CI: 24.3-48.8%)
- Vaginal bleeding: 20.6% (95% CI: 13.9-28.0%)
- Myoma discharge: 24% (95% CI: 14.6-34.8%)
- Vaginal discharge: 14.0% (95% CI: 9.6-19.1%)
- Buttock pain: 10.8% (95% CI: 6.0-16.5%)
- Sacral pain: 10% (95% CI: 8.8-11.2%)
Rare but serious complications 3, 11:
- Skin burns
- Nerve damage
- Bowel injury
- Deep vein thrombosis
- Abdominal wall pain and swelling
- Uterine rupture
- Necrotic tissue obstruction requiring surgical intervention
- Third-degree skin burns
- Persistent lower limb pain or movement disorders
Overall safety profile 11:
- Common adverse events mostly mild and controllable
- Incidence of serious complications extremely low
- Major adverse event rate: 0.2% 3
Prostate HIFU
Primary treatment complications 7:
- Urinary retention: <1-20%
- Urinary tract infections: 1.8-47.9%
- Stress/urinary incontinence: <1-34.3%
- Erectile dysfunction: 20-81.6%
- Recto-urethral fistula: <2%
Focal therapy complications 5:
- Incontinence: 12%
- Erectile dysfunction: 61%
- Treatment-related morbidity reduced by combination of TURP and HIFU 7
Essential Tremor
Safety profile 9:
- Demonstrated in single randomized, sham-surgery-controlled, double-blind trial
- Low rate of complications
- Specific complication rates not detailed in available guidelines
Safety Considerations
Thermal Effects
Temperature monitoring critical 12:
- Thermal Index (TI) maximum of 1 approved by FDA for ocular ultrasound (not to increase tissue temperature >1°C) 12
- Tissue damage dependent on temperature magnitude and duration 12
- Lethal dose at 40°C measured in hours; at 46°C measured in minutes 12
- Coagulation of proteins occurs at 44-46°C; enzyme denaturation at ~50°C 12
Tissue-specific concerns 12:
- Minimal blood flow in certain tissues (lens, cornea, aqueous/vitreous humor) impedes heat dissipation
- Elevated temperatures may persist beyond sonication cessation
- Risk of protein denaturation, increased membrane fluidity, and cell lysis
Cavitation Effects
Microbubble considerations 12:
- Sonication pressure for cavitation inversely proportional to microbubble concentration
- Cavitation magnitude directly proportional to microbubble size and concentration
- Risk of vascular rupture with excessive cavitation
- Particular concern in immune-privileged organs (e.g., eye) where barrier disruption risks autoimmune response
Clinical Outcomes and Quality of Life
Uterine Fibroids
Quality of life improvements 3:
- Significantly greater improvement vs. placebo
- Greater improvement in symptoms and QOL scores at 6 and 12 months compared to baseline
- UAE demonstrates significantly greater UFS-QOL improvement at all time points (6,12,24 months) compared to MRgFUS
Advantages over surgery 3:
- Decreased postprocedural pain
- Reduced narcotic and anti-inflammatory use
- Faster recovery
- Major adverse event rate 0.2% vs. 12.6% for surgical approaches
Prostate Cancer
- Expected improvements in functional outcomes failed to materialize for whole-gland treatment
- Focal therapy shows superior functional preservation
- Patients should be informed that tumor location influences outcomes and limiting apical treatment increases cancer persistence risk 8
Current Recommendations and Guidelines
Uterine Fibroids
- MRgFUS is an appropriate treatment option for symptomatic fibroids in selected patients 3
- Consider for patients desiring uterus preservation, poor surgical candidates, or those with contraindications to surgery
- Counsel patients about higher reintervention rates compared to UAE
Prostate Cancer
- Whole-gland HIFU should not be offered as alternative to established curative treatments for high-risk disease 5
- Focal HIFU should only be performed in clinical trials or prospective registries 5, 8
- Patients considering focal therapy must understand it may not be curative and further treatment may be necessary 8
BPH
- HIFU is investigational and should not be offered outside clinical trials 1
- Additional data required before considering as recommended treatment option 1
Essential Tremor
- MRgFUS thalamotomy is an appropriate treatment for medication-refractory essential tremor meeting specific criteria 9
- Contraindicated for bilateral procedures or contralateral to previous thalamotomy
Future Directions
- Advances in imaging technologies expected to improve efficacy and reduce morbidity
- Investigation of HIFU as salvage and palliative therapy
- Expansion into multiple tumor types and organ systems
- Development as commonplace treatment modality across medical fields
- Long-term oncological outcome studies for prostate cancer
- Randomized controlled trials comparing HIFU to established therapies
- Fertility outcome studies for gynecological applications
- Standardization of treatment protocols and patient selection criteria